Takafumi Minami

Sayama, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 86 publications

Prevalence and Associated Factors of Erectile Dysfunction in Japanese Adolescent and Young Adult (AYA) Male Cancer Survivors.

Prevalence and Associated Factors of Erectile Dysfunction in Japanese Adolescent and Young Adult (AYA) Male Cancer Survivors.

Journal: International journal of urology : official journal of the Japanese Urological Association
Published: January 19, 2026

A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab.

A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab.

Journal: IJU case reports
Published: December 11, 2025

Evaluation of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Photodynamic Diagnosis With 5-Aminolevulinic Acid False-Positive Sites in Non-muscle-Invasive Bladder Cancer.

Evaluation of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Photodynamic Diagnosis With 5-Aminolevulinic Acid False-Positive Sites in Non-muscle-Invasive Bladder Cancer.

Journal: Cureus
Published: August 24, 2025

Treatment strategies for locally advanced and metastatic urothelial carcinoma based on molecular profiles: A Review.

Treatment strategies for locally advanced and metastatic urothelial carcinoma based on molecular profiles: A Review.

Journal: Histology and histopathology
Published: August 05, 2025

Correlation Between First-line Immunotherapy and Second-line TKI Outcomes in Metastatic Renal Cell Carcinoma.

Correlation Between First-line Immunotherapy and Second-line TKI Outcomes in Metastatic Renal Cell Carcinoma.

Journal: Cancer diagnosis & prognosis
Published: July 31, 2025

Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Journal: Urologic oncology
Published: July 29, 2025

Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma.

Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma.

Journal: Anticancer research
Published: June 27, 2025

Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.

Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.

Journal: International journal of urology : official journal of the Japanese Urological Association
Published: May 21, 2025

Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.

Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.

Journal: Translational andrology and urology
Published: April 04, 2025

Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers.

Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers.

Journal: Scientific reports
Published: February 19, 2025

Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin.

Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin.

Journal: In vivo (Athens, Greece)
Published: January 29, 2025

Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy.

Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy.

Journal: Anticancer research
Published: January 26, 2025
Showing 1-12 of 86

Last Updated: 09/26/2026